We are experts in developing novel sub-unit vaccines.

Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner.

Our current portfolio comprises 6 vaccines across livestock species.
Proof of concepts have been generated in > 20 additional vaccine antigens

Current portfolio backed by industry partners

Pre-clinical/Development

Animal Studies/Validation

Filling

Market

BDV

Partnered

RHDV

CrisBio
Partnered

PCV2

CrisBio
Partnered

PCV2

TopBac

African Swine Fever (ASF)

CrisBio
Partnered

ASF Diagnostics

CrisBio
Partnered

Avian influenza

CrisBio

Diagnostics (human)

CrisBio
Partnered

Strategy

Value through collaborations

Our go to market strategy is inherently linked to collaborations. We offer:

  • Development of tailor-made baculovirus vectors optimized for industrial production.
  • Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®.
  • Supply of recombinant proteins produced in CrisBio® through license agreements.
  • Development of proprietary portfolios.
Strategy | Algenex

Our team

Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.

Management

Claudia Jimenez

Claudia Jimenez

General Director

+ More info
x

Claudia Jimenez

General Director

Claudia has 20 years of experience and a proven record of accomplishment in corporate development, investor relations and communications. She started her career in corporate finance at WestLB AG in Germany, where she managed mergers and acquisition (M&A) projects across various industries. Following the completion of her MBA at Instituto de Empresa in 2005, she joined the biotechnology company TiGenix, taking responsibility for corporate development and leading the company’s partnering efforts that culminated in a deal with Takeda worth up to €380M. Following the company’s Nasdaq IPO, Claudia became responsible for investor relations and corporate communications until the completion of the acquisition of TiGenix by Takeda in 2018.

José Escribano

José Escribano

Founder and CSO

+ More info
x

José Escribano

Founder and CSO

Jose is a specialist in viral infectious diseases and in the development of biotechnology applications of viruses, with more than 120 scientific contributions in international journals and numerous licensed patents. He is on the editorial board of several virology and biotechnology journals. José is a graduate and Ph.D from Complutense University of Madrid in Veterinary Medicine and carried out postdoctoral studies in different institutions of USA. Jose served as Research Professor in a Spanish scientific institution and has over 25 years of experience in science management. As entrepreneur, he is co-founder of ALGENEX and LogicBiology.

Virginia Gonzalez

Virginia Gonzalez

CFO

+ More info
x

Virginia Gonzalez

CFO

Virginia has more than 20 years’ experience in finance. She started her career in the finance department of Decathlon after completing her degree in Business Administration at the University of Oviedo, Spain. She later joined the biotechnology company TiGenix, a dual listed Company (Nasdaq & Euronext ) which was acquired by Takeda 2019. During her 13 years at TiGenx she held different roles of responsibility, including finance director and head of controlling and consolidation. Virginia holds a master in Business Administration from CEF and an Advance Management Program from Instituto de Empresa, Madrid.

Romy Dalton

Romy Dalton

COO

+ More info
x

Romy Dalton

COO

Romy has more than 17 years of experience on Molecular Biology and Virology and eleven scientific publications in peer reviewed journals. She has worked first as a researcher and then as a Project Leader at several Biotech Companies. She joined Algenex more than three years ago in the position of Chief Operations Officer and manages the Comercial Agreements, Human Resources, Patent Portfolio and supervises the scientific projects.

Strategic Advisory Board

Dr. René Aerts

Dr. René Aerts

Ex Merck Exec. with global responsability for Animal Health

+ More info
x

Dr. René Aerts

Ex Merck Exec. with global responsability for Animal Health

Dr. René Aerts is the Founder of RA-Consultancy BV and currently serves as Partner at NovioCap BV. He retired from Merck/MSD Animal Health in 2013 where he had been a member of the Executive Committee since 2008 as Global Head Vaccine Research. He previous held senior positions in Manufacturing Operations, Regulatory Affairs and R&D at Intervet International. He holds non-executive and Advisory Board positions at AGC Biologics (USA), The Jenner Institute (UK), ImmunoValley (NL), Schothorst Feed Research BV (NL) and Alternative Gene Expression Ltd (ES). Mr. Aerts received a PhD in Bioanalytics and Pharmacochemistry from the Free University of Amsterdam in 1990.

Jean Stéphenne

Jean Stéphenne

Ex member of the Corp. Exec. Team of GSK an CEO of GSK Biologicals (now GSK Vaccines)

+ More info
x

Jean Stéphenne

Ex member of the Corp. Exec. Team of GSK an CEO of GSK Biologicals (now GSK Vaccines)

Jean Stéphenne is a highly-experienced life sciences executive, who has served in senior leadership roles at a large number of biotechnology and pharmaceutical companies, most recently as Chairman of TiGenix (acquired by Takeda in 2019). Jean was previously a Member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chief Executive of GSK Biologicals (now GSK Vaccines). During his 40-year tenure, he grew a company of 50 people into a fully integrated worldwide leader in vaccine development, with 12,000 employees. He currently serves on the Board of various life sciences companies including Vaxxilon (DE), OncoDNA (BE), BoneTherapeutics (BE), CureVac (DE) and Bepharbel (BE) as well as in biotech investments funds Vesalius (BE) and Merieux Investments (FR). For his contribution to the Belgian economy and global public health, he has received diverse business recognitions and was honored with various titles by the Belgian and British governments.

Claudia D´Augusta

Claudia D´Augusta

CFO Vectivbio

+ More info
x

Claudia D´Augusta

CFO Therachon

Claudia D’Augusta has over 20 years of experience in corporate finance, 14 of which have been in the life sciences sector. She currently serves as CFO of VectviBio a spin off of Therachon (sold to Pfizer in 1H 2019 for a total deal value of 810M USD) a Swiss clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions.

Roberto Barzi

Roberto Barzi

Investor

+ More info
x

Roberto Barzi

Investor

Roberto Barzi is an investor in the healthcare sector, where he has been active for the past decade. Originally part of 3i’s global healthcare team, he later founded Fort Rock Capital, a specialist investor in the space. He is the Managing Partner of VitaTech (lifesciences), based in Luxembourg and active across Europe. He currently serves on the boards of Vasopharm GmbH (Germany, traumatic brain injury), GNS Healthcare (USA, AI and digital health) and Medinet (UK, clinical services).

Nicola Zambon

Nicola Zambon

Investor

+ More info
x

Nicola Zambon

Investor

Nicola Zambon has 23 years of M&A and principal investment experience. He is the founder and managing partner of Cleon Capital, an independent advisory and investment company with offices in Madrid and Milan. Prior to founding Cleon, he served as director and partner of the private equity firms Investindustrial and Ergon Capital. Nicola is a board member of 15 companies located in various jurisdictions across Europe.